"Will the real CFS patients, please stand up. Oh, wait, I see you can't. Well, just send me an e-mail."
Tina
To make things even crazier they report that the CDC samples they tested were negative for XMRV as well.
Initial analysis shows that the FDA test results are generally consistent with CDC, with no XMRV-positive results in the CFS samples CDC provided (34 samples were tested, 31 were negative, 3 were indeterminate)
"Of the 37 patients in the Alter study, 25 came from Dr. Komaroff's clinic, and the other 12 came from the practices of David Bell and Paul Cheney. (Komaroff was able to confirm that of the 25 patients from his clinic, all 25 met the 1988 Holmes criteria for CFS, and 21 of those 25 also met the 1994 Fukuda criteria. No information was provided on the criteria applicable to the other 12 patients.)"
Lots more we still have to learn and analyze about the cohorts.
Dr Alter: "To demonstrate that further we in our paper, we recalled 8 patients from Dr Komaroff. 15 years later 7 of the 8 still had the virus but the virus had changed within the patient over that time. These are minor variations, very characteristic of the mutation in the patient. And again suggest that this is a real phenomenon in the patient and not a laboratory contamination."
...
Also, does mutation in the patient potentially explain different symptom clusters in different patients, and symptom changes in the same patient over time?
Great article, Cort!
I've been trying to keep track of the cohort used in this study, hoping to post a summary backed up by authority. Not ready for prime time yet...
But, I can note one correction that could be made in your article - where you state "The Alter study participants were provided by Dr. Komaroff from patients at his clinic. (Interestingly only half of them met the Fukuda criteria while all met the Holmes criteria.")
It would be more correct to say: "Of the 37 patients in the Alter study, 25 came from Dr. Komaroff's clinic, and the other 12 came from the practices of David Bell and Paul Cheney. (Komaroff was able to confirm that of the 25 patients from his clinic, all 25 met the 1988 Holmes criteria for CFS, and 21 of those 25 also met the 1994 Fukuda criteria. No information was provided on the criteria applicable to the other 12 patients.)"
I don't think the information about the source of the 12 non-Komaroff patients was in the PNAS paper - I think it was mentioned by McCleary in her good article, which looked back to the 1993 paper on mycoplasma fermantans that was published on these patients.
Also note - of the 25 Komaroff sample patients, 24 of 25 (96%) were positive according to the PNAS paper. This must mean that 8 of 12 of the Bell or Cheney patients (67%) were positive (implied not stated).
Lots more we still have to learn and analyze about the cohorts. But, I have seen some commentators express concern that with each "looser" case definition of CFS, there is not only an issue of bringing in people who wouldn't meet more "stringent" definitions, but there is also an issue of losing from the case definition people who meet the "stricter" criteria.
Anika
Not so very cynical, OS. Yes, AIDS patients require meds, very expensive meds. Combine today's recession with sky-rocketing health costs, medicare cuts, the price of insurance premiums, powerful insurance lobbyists, boomers who are going to hit medicare like no other generation before, and ask yourself are we in any better position today for another AIDS epidemic? Call me cynical, but I think it's going to be a long time before help comes our way -- insurance paid help. Best bet, get in a drug trial.
Anika, I love your idea of the cohort summary. One thing to consider is that these were pre-filtered patients, either self-selected to some of the best biological ME/CFS practitioners in the US at the time, and/or also screened extensively by these ME/CFS physicians "in the know". So while they did indeed meet the Holmes and/or Fukuda criteria, they also undoubtedly met the unofficial "Komaroff, Cheney, and Bell Criteria".
.
Great article, Cort. The best of what Cort Johnson does best. You not only translate the paper into plain English, you explain the implications of the findings. This is what has made me a PR fan for years.
Actually the slide just before that one specified that it was whole blood spiked with XMRV positive cells, and plasma spiked with supernatent containing XMRV cells. I think it was also mentioned at the Blood Products Advisory Committee meeting.
I'm not sure this is inconsistent, given that Lo/FDA found MLVs but not XMRV. The precise wording used on the FDA website to report their negative XMRV findings for CDC samples is interesing (my italics below):
So the FDA found no XMRV in their own samples and none in the CDC ones either. But did the FDA find any evidence of MLVs in the CDC samples? that might tell us more.
And do we generally need fewer acronyms in CFS research?
" Although three MLVs were found one MLV dominated the rest, infecting 86% of the CFS patients."
Is that a typo ? 86% was also exactly the total % of ME patients with any MLVs.
or does that mean that some patients had more than one type of MLV.
Other thoughts: Does the "not exactly XMRV" result tie in with earlier comments by Mikovits about some kind of editing being done by the cell's defences. Is it possible that slight variations in procedure/timing either allow the editing to complete, or retain the pre-edited pure XMRV (original study). I look forward to Mikovits and other researchers soon sharing their interpretations just like after the 2009 Science publication.
re: Mitos.... I sure would like more investigation into them also. Too bad the Myhill study wasn't followed up - it would be nice biomarker(s) to match up to the results being published.